09955 CLOUDR
- 3.000
- +0.060+2.04%
CLOUDR News
智雲健康：年報2023
ClouDr Launches Digital Employee to Improve Online-to-Offline Operation Services
ClouDr Group (HKG:9955) recently launched its first digital employee, Yan Ruyu — Xiaoyu, to optimize and upgrade the workflow and operation mode of its online-to-offline (O2O) operation services. The
Zhiyun Health (09955) launches the first digital employee to help improve the efficiency of out-of-hospital solutions
Zhiyun Health (09955) announced that recently, as a leader in digitally empowering pharmacy operations, the company recently launched...
Changes in Hong Kong stocks | Zhiyun Health (09955) reached a high of nearly 13%, and the company's revenue continues to grow, P2M strategy opens up profit space
Zhiyun Health (09955) reached a high of nearly 13%. As of press release, it rose 8.82% to HK$2.96, with a turnover of HK$56.5093 million.
Zhiyun Health (09955): Unusual share price and trading volume fluctuations The management team is still confident about the company's long-term prospects
Zhitong Finance App News, Zhiyun Health (09955) announced that the company's shares have recently experienced a drop in transaction price and an increase in trading volume. After making all reasonable enquiries about the Company's circumstances, the Board confirmed that it was unaware of any reason for the recent fluctuations in transaction prices and volume, or any information that must be published to avoid causing a false market in the Company's securities, or any insider information required to be disclosed in accordance with Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). The board of directors confirmed that the company's business operations are in good condition and that the management team has maintained a long-term relationship with the company
Changes in Hong Kong stocks | Zhiyun Health (09955) rose more than 7% in 23 years, the company's revenue maintained rapid growth and turned a loss into a profit in the fourth quarter
The Zhitong Finance App learned that Zhiyun Health (09955) rose by more than 7% and rose 7.19% at press time to HK$3.13, with a turnover of HK$21.77 million. According to the news, on March 21, financial reports showed that in 2023, Zhiyun Health's revenue continued to grow rapidly, with revenue reaching 3.69 billion yuan, an increase of 23.5% over the previous year. Non-IFRS (non-IFRS) adjusted net loss narrowed to 75.1 million yuan, a year-on-year decrease of 77.4%. The fourth quarter became the company's first profitable quarter, turning losses into profits in a single quarter. Financial reports show that Zhiyun Health's three major business boards
Market Cool On ClouDr Group Limited's (HKG:9955) Revenues Pushing Shares 47% Lower
ClouDr Group Limited (HKG:9955) shareholders that were waiting for something to happen have been dealt a blow with a 47% share price drop in the last month. The recent drop completes a disastrous t
Zhiyun Health (9955.HK): Cao Yun sees the moon, leading domestic chronic disease management leaders meet an inflection point in performance
Summary: The light boat has already passed Wanjou Mountain. It is small but beautiful and more resilient. Due to the combined impact of various factors, the performance of the Hong Kong stock market has not been as good as expected. However, expectations of interest rate cuts in 2024 are certain. Regulatory reform measures continue to advance, and expectations of market recovery have been further strengthened. “undervaluation”, which has always been criticized by investors, will instead further highlight investment value. In particular, some small but beautiful companies, small market capitalization, and continuous improvement in performance may bring us a surprise. Zhiyun Health (09955.HK), which was listed on the Hong Kong Stock Exchange in July 2022, specializes in “AI+ healthcare” as
ClouDr Group's Net Loss Shrinks 81% in 2023 as Revenue Rises 23.5%
ClouDr Group (HKG:9955) narrowed its net loss by 80.7% to 327.34 million yuan in the year ended Dec. 31, 2023, against 1.69 billion yuan a year ago, according to a Thursday filing with the Hong Kong S
Zhiyun Health (09955) Digitalization empowers pharmacy operations to improve quality and efficiency
More than 200,000 pharmacies across the country have installed the Zhiyun Health Pharmacy SaaS system. The Zhiyun Health Out-of-Hospital platform links upstream and downstream partners outside the hospital, carries services and products, and relies on a strong central platform to support the efficient operation of out-of-hospital business.
The rapid development of “Internet+Healthcare” Zhiyun Health (09955)'s revenue in 2023 increased 23.5% year-on-year to 3.69 billion yuan
Zhiyun Health (09955) announced its annual results for the year ended December 31, 2023, with group revenue of RMB 36...
A Sino-German business exchange meeting was held in Beijing. Zhiyun Health (09955) explores new opportunities for international cooperation
The Zhitong Finance App learned that on March 18, the China Small and Medium Enterprises International Cooperation Association and the German Federal Federation of Small and Medium Enterprises held a bilateral exchange meeting in Beijing. Shao Ning, Chairman of the China SME International Cooperation Association, Dr. Jochen Leonhardt, Chairman of the Board of the German SME Federation, Shan Lipo, Vice President and Secretary General of the China SME International Cooperation Association and Director of the China SME Development Promotion Center, representatives of Chinese enterprises, and representatives of German enterprises gathered to have friendly exchanges and discuss opportunities for cooperation on the macro environment, development status and work direction of SME international cooperation. Zhiyun Health (09955) Vice
Understand the 2023 annual results of Zhiyun Health (09955.HK) in one picture
On March 21, Zhiyun Health (09955.HK) officially announced the 2023 performance report. Let me take you to understand the specific results in a picture.
CLOUDR: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Analysts Expect Breakeven For ClouDr Group Limited (HKG:9955) Before Long
With the business potentially at an important milestone, we thought we'd take a closer look at ClouDr Group Limited's (HKG:9955) future prospects. ClouDr Group Limited, an investment holding company,
Zhiyun Health (09955.HK) plans to hold a board meeting on March 21 to approve annual results
Gelonghui, March 11, 丨 Zhiyun Health (09955.HK) issued an announcement. The board of directors hereby announces that a board meeting will be held on March 21, 2024 (Thursday) to consider and approve the annual results of the company and its subsidiaries for the year ended 31 December 2023 and to deal with other matters.
CLOUDR: DATE OF BOARD MEETING
ClouDr Launches Diabetes Tablets; Shares Up 3%
ClouDr (HKG:9955) launched its Hetangjin-branded dapagliflozin tablets for type 2 diabetes, according to a Monday filing with the Hong Kong bourse. China's medical products administrator approved the
Zhiyun Health (09955): Proprietary products and Tangjing Dagliflozin tablets have been marketed and released
Zhitong Finance App News, Zhiyun Health (09955) announced that the marketing meeting for the group's proprietary products and Tangjingdaglinet tablets with sales rights will be held on March 9, 2024, marking that the product has entered the marketing and sales stage after officially obtaining a drug registration certificate (Sinopharm license H20234636) issued by the State Drug Administration on December 13, 2023. According to reports, dapagliflozin tablets are the only essential drug in the sodium-glucose co-transporter 2 (SGLT-2) inhibitor class. Dapagliflozin was approved to enter the Chinese market in 2017 and included in China's medical insurance category B in 2019
Changes in Hong Kong stocks | Zhiyun Health (09955) once rose nearly 20%. The company confirmed good business operations and reached a strategic cooperation with China Resources Torch
Zhiyun Health (09955) rose nearly 20% at the beginning of the session. The stock continued to decline yesterday and eventually closed down nearly 15%. As of press release, it rose 14.6% to HK$4.63, with a turnover of HK$3.672,300.
Analysis
Price Target
No Data
